#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-16	Interhemispheric	_
1-2	17-29	connectivity	_
1-3	30-33	and	_
1-4	34-45	hemispheric	_
1-5	46-60	specialization	_
1-6	61-63	in	_
1-7	64-77	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-8	78-86	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-9	87-90	and	_
1-10	91-96	their	_
1-11	97-107	unaffected	_
1-12	108-116	siblings	_
1-13	117-128	Hemispheric	_
1-14	129-140	integration	_
1-15	141-144	and	_
1-16	145-159	specialization	_
1-17	160-163	are	_
1-18	164-167	two	_
1-19	168-177	prominent	_
1-20	178-192	organizational	_
1-21	193-203	principles	_
1-22	204-207	for	_
1-23	208-219	macroscopic	_
1-24	220-225	brain	_
1-25	226-234	function	_
1-26	235-236	.	_

2-1	237-248	Impairments	_
2-2	249-251	of	_
2-3	252-268	interhemispheric	_
2-4	269-280	cooperation	_
2-5	281-285	have	_
2-6	286-290	been	_
2-7	291-299	reported	_
2-8	300-302	in	_
2-9	303-316	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-10	317-325	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-11	326-327	,	_
2-12	328-331	but	_
2-13	332-339	whether	_
2-14	340-344	such	_
2-15	345-358	abnormalities	_
2-16	359-365	should	_
2-17	366-368	be	_
2-18	369-379	attributed	_
2-19	380-382	to	_
2-20	383-390	effects	_
2-21	391-393	of	_
2-22	394-401	illness	_
2-23	402-404	or	_
2-24	405-413	familial	_
2-25	414-418	risk	_
2-26	419-426	remains	_
2-27	427-439	inconclusive	_
2-28	440-441	.	_

3-1	442-450	Moreover	_
3-2	451-452	,	_
3-3	453-455	it	_
3-4	456-458	is	_
3-5	459-466	unclear	_
3-6	467-470	how	_
3-7	471-484	abnormalities	_
3-8	485-487	in	_
3-9	488-504	interhemispheric	_
3-10	505-517	connectivity	_
3-11	518-524	impact	_
3-12	525-536	hemispheric	_
3-13	537-551	specialization	_
3-14	552-553	.	_

4-1	554-556	To	_
4-2	557-564	address	_
4-3	565-570	these	_
4-4	571-580	questions	_
4-5	581-582	,	_
4-6	583-585	we	_
4-7	586-595	performed	_
4-8	596-604	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
4-9	605-614	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
4-10	615-622	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
4-11	623-624	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
4-12	625-628	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
4-13	629-630	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
4-14	631-633	in	_
4-15	634-635	a	_
4-16	636-641	large	_
4-17	642-648	cohort	_
4-18	649-651	of	_
4-19	652-655	253	_
4-20	656-668	participants	_
4-21	669-670	,	_
4-22	671-680	including	_
4-23	681-683	84	_
4-24	684-697	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-25	698-706	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-26	707-708	,	_
4-27	709-712	106	_
4-28	713-715	of	_
4-29	716-721	their	_
4-30	722-732	unaffected	_
4-31	733-741	siblings	_
4-32	742-745	and	_
4-33	746-748	63	_
4-34	749-756	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-35	757-765	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-36	766-767	.	_

5-1	768-784	Interhemispheric	_
5-2	785-797	connectivity	_
5-3	798-801	and	_
5-4	802-813	hemispheric	_
5-5	814-828	specialization	_
5-6	829-833	were	_
5-7	834-844	calculated	_
5-8	845-849	from	_
5-9	850-863	resting-state	_
5-10	864-874	functional	_
5-11	875-887	connectivity	_
5-12	888-889	,	_
5-13	890-893	and	_
5-14	894-902	compared	_
5-15	903-909	across	_
5-16	910-916	groups	_
5-17	917-918	.	_

6-1	919-926	Results	_
6-2	927-933	showed	_
6-3	934-938	that	_
6-4	939-952	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-5	953-961	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-6	962-969	exhibit	_
6-7	970-975	lower	_
6-8	976-992	interhemispheric	_
6-9	993-1005	connectivity	_
6-10	1006-1008	as	_
6-11	1009-1017	compared	_
6-12	1018-1020	to	_
6-13	1021-1029	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-14	1030-1033	and	_
6-15	1034-1042	siblings	_
6-16	1043-1044	.	_

7-1	1045-1047	In	_
7-2	1048-1056	addition	_
7-3	1057-1058	,	_
7-4	1059-1067	patients	_
7-5	1068-1074	showed	_
7-6	1075-1081	higher	_
7-7	1082-1088	levels	_
7-8	1089-1091	of	_
7-9	1092-1103	hemispheric	_
7-10	1104-1118	specialization	_
7-11	1119-1121	as	_
7-12	1122-1130	compared	_
7-13	1131-1133	to	_
7-14	1134-1142	siblings	_
7-15	1143-1144	.	_

8-1	1145-1150	Level	_
8-2	1151-1153	of	_
8-3	1154-1170	interhemispheric	_
8-4	1171-1183	connectivity	_
8-5	1184-1187	and	_
8-6	1188-1199	hemispheric	_
8-7	1200-1214	specialization	_
8-8	1215-1225	correlated	_
8-9	1226-1230	with	_
8-10	1231-1239	duration	_
8-11	1240-1242	of	_
8-12	1243-1250	illness	_
8-13	1251-1253	in	_
8-14	1254-1262	patients	_
8-15	1263-1264	.	_

9-1	1265-1267	No	_
9-2	1268-1279	significant	_
9-3	1280-1291	alterations	_
9-4	1292-1296	were	_
9-5	1297-1307	identified	_
9-6	1308-1310	in	_
9-7	1311-1319	siblings	_
9-8	1320-1328	relative	_
9-9	1329-1331	to	_
9-10	1332-1340	controls	_
9-11	1341-1343	on	_
9-12	1344-1348	both	_
9-13	1349-1361	measurements	_
9-14	1362-1363	.	_

10-1	1364-1375	Furthermore	_
10-2	1376-1377	,	_
10-3	1378-1389	alterations	_
10-4	1390-1392	in	_
10-5	1393-1409	interhemispheric	_
10-6	1410-1422	connectivity	_
10-7	1423-1433	correlated	_
10-8	1434-1438	with	_
10-9	1439-1446	changes	_
10-10	1447-1449	in	_
10-11	1450-1461	hemispheric	_
10-12	1462-1476	specialization	_
10-13	1477-1479	in	_
10-14	1480-1488	patients	_
10-15	1489-1497	relative	_
10-16	1498-1500	to	_
10-17	1501-1509	controls	_
10-18	1510-1513	and	_
10-19	1514-1522	siblings	_
10-20	1523-1524	.	_

11-1	1525-1530	Taken	_
11-2	1531-1539	together	_
11-3	1540-1541	,	_
11-4	1542-1547	these	_
11-5	1548-1555	results	_
11-6	1556-1563	suggest	_
11-7	1564-1568	that	_
11-8	1569-1574	lower	_
11-9	1575-1591	interhemispheric	_
11-10	1592-1604	connectivity	_
11-11	1605-1608	and	_
11-12	1609-1619	associated	_
11-13	1620-1633	abnormalities	_
11-14	1634-1636	in	_
11-15	1637-1648	hemispheric	_
11-16	1649-1663	specialization	_
11-17	1664-1667	are	_
11-18	1668-1676	features	_
11-19	1677-1679	of	_
11-20	1680-1691	established	_
11-21	1692-1699	illness	_
11-22	1700-1701	,	_
11-23	1702-1708	rather	_
11-24	1709-1713	than	_
11-25	1714-1716	an	_
11-26	1717-1727	expression	_
11-27	1728-1730	of	_
11-28	1731-1742	preexistent	_
11-29	1743-1751	familial	_
11-30	1752-1756	risk	_
11-31	1757-1760	for	_
11-32	1761-1774	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-33	1775-1776	.	_

12-1	1777-1787	Highlights	_
12-2	1788-1801	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-3	1802-1810	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-4	1811-1815	show	_
12-5	1816-1821	lower	_
12-6	1822-1838	interhemispheric	_
12-7	1839-1851	connectivity	_
12-8	1852-1853	(	_
12-9	1854-1856	IC	_
12-10	1857-1858	)	_
12-11	1859-1867	compared	_
12-12	1868-1870	to	_
12-13	1871-1879	siblings	_
12-14	1880-1883	and	_
12-15	1884-1892	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-16	1893-1894	.	_

13-1	1895-1900	Lower	_
13-2	1901-1903	IC	_
13-3	1904-1906	is	_
13-4	1907-1917	associated	_
13-5	1918-1922	with	_
13-6	1923-1929	higher	_
13-7	1930-1941	hemispheric	_
13-8	1942-1956	specialization	_
13-9	1957-1958	(	_
13-10	1959-1961	HS	_
13-11	1962-1963	)	_
13-12	1964-1966	in	_
13-13	1967-1975	patients	_
13-14	1976-1977	.	_

14-1	1978-1986	Siblings	_
14-2	1987-1989	do	_
14-3	1990-1993	not	_
14-4	1994-1998	show	_
14-5	1999-2006	changes	_
14-6	2007-2009	on	_
14-7	2010-2012	IC	_
14-8	2013-2016	and	_
14-9	2017-2019	HS	_
14-10	2020-2028	relative	_
14-11	2029-2031	to	_
14-12	2032-2040	controls	_
14-13	2041-2042	.	_

15-1	2043-2055	Connectivity	_
15-2	2056-2063	metrics	_
15-3	2064-2065	(	_
15-4	2066-2068	IC	_
15-5	2069-2070	,	_
15-6	2071-2073	HS	_
15-7	2074-2075	)	_
15-8	2076-2085	correlate	_
15-9	2086-2090	with	_
15-10	2091-2099	duration	_
15-11	2100-2102	of	_
15-12	2103-2110	illness	_
15-13	2111-2113	in	_
15-14	2114-2122	patients	_
15-15	2123-2124	.	_

16-1	2125-2133	Material	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
16-2	2134-2137	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
16-3	2138-2145	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
16-4	2146-2158	Participants	_
16-5	2159-2160	A	_
16-6	2161-2166	total	_
16-7	2167-2169	of	_
16-8	2170-2173	253	_
16-9	2174-2186	participants	_
16-10	2187-2188	,	_
16-11	2189-2198	including	_
16-12	2199-2201	84	_
16-13	2202-2215	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-14	2216-2224	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-15	2225-2226	,	_
16-16	2227-2230	106	_
16-17	2231-2233	of	_
16-18	2234-2239	their	_
16-19	2240-2250	unaffected	_
16-20	2251-2259	siblings	_
16-21	2260-2263	and	_
16-22	2264-2266	63	_
16-23	2267-2274	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-24	2275-2283	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-25	2284-2285	,	_
16-26	2286-2290	were	_
16-27	2291-2300	recruited	_
16-28	2301-2303	at	_
16-29	2304-2307	the	_
16-30	2308-2318	University	_
16-31	2319-2326	Medical	_
16-32	2327-2333	Center	_
16-33	2334-2341	Utrecht	_
16-34	2342-2349	between	_
16-35	2350-2359	September	_
16-36	2360-2364	2004	_
16-37	2365-2368	and	_
16-38	2369-2374	April	_
16-39	2375-2379	2008	_
16-40	2380-2381	,	_
16-41	2382-2384	as	_
16-42	2385-2389	part	_
16-43	2390-2392	of	_
16-44	2393-2396	the	_
16-45	2397-2404	Genetic	_
16-46	2405-2409	Risk	_
16-47	2410-2413	and	_
16-48	2414-2421	Outcome	_
16-49	2422-2424	of	_
16-50	2425-2434	Psychosis	_
16-51	2435-2436	(	_
16-52	2437-2442	GROUP	_
16-53	2443-2444	)	_
16-54	2445-2450	study	_
16-55	2451-2452	.	_

17-1	2453-2456	The	_
17-2	2457-2462	GROUP	_
17-3	2463-2468	study	_
17-4	2469-2472	was	_
17-5	2473-2482	conducted	_
17-6	2483-2485	by	_
17-7	2486-2490	four	_
17-8	2491-2501	university	_
17-9	2502-2513	psychiatric	_
17-10	2514-2521	centers	_
17-11	2522-2525	and	_
17-12	2526-2531	their	_
17-13	2532-2542	affiliated	_
17-14	2543-2549	mental	_
17-15	2550-2556	health	_
17-16	2557-2561	care	_
17-17	2562-2574	institutions	_
17-18	2575-2577	in	_
17-19	2578-2581	the	_
17-20	2582-2593	Netherlands	_
17-21	2594-2595	.	_

18-1	2596-2599	The	_
18-2	2600-2607	medical	_
18-3	2608-2614	ethics	_
18-4	2615-2624	committee	_
18-5	2625-2627	of	_
18-6	2628-2631	the	_
18-7	2632-2642	University	_
18-8	2643-2650	Medical	_
18-9	2651-2657	Center	_
18-10	2658-2665	Utrecht	_
18-11	2666-2674	approved	_
18-12	2675-2678	the	_
18-13	2679-2686	current	_
18-14	2687-2692	study	_
18-15	2693-2694	.	_

19-1	2695-2698	All	_
19-2	2699-2707	subjects	_
19-3	2708-2716	provided	_
19-4	2717-2724	written	_
19-5	2725-2733	informed	_
19-6	2734-2741	consent	_
19-7	2742-2747	prior	_
19-8	2748-2750	to	_
19-9	2751-2764	participation	_
19-10	2765-2766	.	_

20-1	2767-2770	For	_
20-2	2771-2774	all	_
20-3	2775-2787	participants	_
20-4	2788-2789	,	_
20-5	2790-2798	presence	_
20-6	2799-2801	or	_
20-7	2802-2809	absence	_
20-8	2810-2812	of	_
20-9	2813-2820	current	_
20-10	2821-2824	and	_
20-11	2825-2833	lifetime	_
20-12	2834-2849	psychopathology	_
20-13	2850-2853	was	_
20-14	2854-2865	established	_
20-15	2866-2871	using	_
20-16	2872-2875	the	_
20-17	2876-2889	Comprehensive	_
20-18	2890-2900	Assessment	_
20-19	2901-2903	of	_
20-20	2904-2912	Symptoms	_
20-21	2913-2916	and	_
20-22	2917-2924	History	_
20-23	2925-2926	(	_
20-24	2927-2931	CASH	_
20-25	2932-2933	)	_
20-26	2934-2935	.	_

21-1	2936-2940	This	_
21-2	2941-2956	semi-structured	_
21-3	2957-2966	interview	_
21-4	2967-2969	is	_
21-5	2970-2978	designed	_
21-6	2979-2981	to	_
21-7	2982-2988	obtain	_
21-8	2989-3002	comprehensive	_
21-9	3003-3014	information	_
21-10	3015-3017	on	_
21-11	3018-3025	current	_
21-12	3026-3029	and	_
21-13	3030-3034	past	_
21-14	3035-3040	signs	_
21-15	3041-3044	and	_
21-16	3045-3053	symptoms	_
21-17	3054-3056	of	_
21-18	3057-3062	major	_
21-19	3063-3074	psychiatric	_
21-20	3075-3084	disorders	_
21-21	3085-3086	,	_
21-22	3087-3096	premorbid	_
21-23	3097-3108	functioning	_
21-24	3109-3110	,	_
21-25	3111-3127	sociodemographic	_
21-26	3128-3134	status	_
21-27	3135-3136	,	_
21-28	3137-3146	treatment	_
21-29	3147-3148	,	_
21-30	3149-3152	and	_
21-31	3153-3159	course	_
21-32	3160-3162	of	_
21-33	3163-3170	illness	_
21-34	3171-3172	.	_

22-1	3173-3181	Patients	_
22-2	3182-3186	were	_
22-3	3187-3195	included	_
22-4	3196-3198	if	_
22-5	3199-3203	they	_
22-6	3204-3207	met	_
22-7	3208-3218	Diagnostic	_
22-8	3219-3222	and	_
22-9	3223-3234	Statistical	_
22-10	3235-3241	Manual	_
22-11	3242-3244	of	_
22-12	3245-3251	Mental	_
22-13	3252-3261	Disorders	_
22-14	3262-3268	fourth	_
22-15	3269-3276	edition	_
22-16	3277-3278	(	_
22-17	3279-3285	DSM-IV	_
22-18	3286-3287	)	_
22-19	3288-3296	criteria	_
22-20	3297-3300	for	_
22-21	3301-3314	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-22	3315-3317	or	_
22-23	3318-3333	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
22-24	3334-3342	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
22-25	3343-3344	.	_

23-1	3345-3352	Symptom	_
23-2	3353-3361	severity	_
23-3	3362-3365	was	_
23-4	3366-3374	assessed	_
23-5	3375-3380	using	_
23-6	3381-3384	the	_
23-7	3385-3393	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-8	3394-3397	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-9	3398-3406	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-10	3407-3415	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-11	3416-3421	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-12	3422-3423	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-13	3424-3429	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-14	3430-3431	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-15	3432-3433	.	_

24-1	3434-3437	The	_
24-2	3438-3444	dosage	_
24-3	3445-3447	of	_
24-4	3448-3461	antipsychotic	_
24-5	3462-3472	medication	_
24-6	3473-3481	patients	_
24-7	3482-3486	were	_
24-8	3487-3493	taking	_
24-9	3494-3496	at	_
24-10	3497-3500	the	_
24-11	3501-3505	time	_
24-12	3506-3508	of	_
24-13	3509-3517	scanning	_
24-14	3518-3522	were	_
24-15	3523-3532	converted	_
24-16	3533-3535	to	_
24-17	3536-3537	a	_
24-18	3538-3552	chlorpromazine	_
24-19	3553-3563	equivalent	_
24-20	3564-3570	dosage	_
24-21	3571-3572	.	_

25-1	3573-3581	Patients	_
25-2	3582-3585	and	_
25-3	3586-3594	siblings	_
25-4	3595-3605	originated	_
25-5	3606-3610	from	_
25-6	3611-3614	120	_
25-7	3615-3621	unique	_
25-8	3622-3630	families	_
25-9	3631-3634	and	_
25-10	3635-3643	included	_
25-11	3644-3646	48	_
25-12	3647-3662	patient-sibling	_
25-13	3663-3668	pairs	http://maven.renci.org/NeuroBridge/neurobridge#Pain
25-14	3669-3671	or	_
25-15	3672-3680	triplets	_
25-16	3681-3682	.	_

26-1	3683-3686	The	_
26-2	3687-3694	control	_
26-3	3695-3700	group	_
26-4	3701-3710	comprised	_
26-5	3711-3713	63	_
26-6	3714-3722	subjects	_
26-7	3723-3727	from	_
26-8	3728-3730	57	_
26-9	3731-3739	families	_
26-10	3740-3741	.	_

27-1	3742-3743	A	_
27-2	3744-3750	family	_
27-3	3751-3765	identification	_
27-4	3766-3770	code	_
27-5	3771-3772	(	_
27-6	3773-3779	family	_
27-7	3780-3782	ID	_
27-8	3783-3784	)	_
27-9	3785-3788	was	_
27-10	3789-3797	assigned	_
27-11	3798-3800	to	_
27-12	3801-3806	every	_
27-13	3807-3814	subject	_
27-14	3815-3817	to	_
27-15	3818-3822	keep	_
27-16	3823-3828	track	_
27-17	3829-3831	of	_
27-18	3832-3837	their	_
27-19	3838-3847	pedigrees	_
27-20	3848-3849	.	_

28-1	3850-3858	Siblings	_
28-2	3859-3862	and	_
28-3	3863-3870	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
28-4	3871-3879	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
28-5	3880-3884	were	_
28-6	3885-3893	excluded	_
28-7	3894-3897	for	_
28-8	3898-3901	any	_
28-9	3902-3909	current	_
28-10	3910-3912	or	_
28-11	3913-3921	previous	_
28-12	3922-3931	psychotic	_
28-13	3932-3940	disorder	_
28-14	3941-3942	.	_

29-1	3943-3945	In	_
29-2	3946-3954	addition	_
29-3	3955-3956	,	_
29-4	3957-3965	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
29-5	3966-3970	were	_
29-6	3971-3979	examined	_
29-7	3980-3984	with	_
29-8	3985-3988	the	_
29-9	3989-3995	Family	_
29-10	3996-4005	Interview	_
29-11	4006-4009	for	_
29-12	4010-4017	Genetic	_
29-13	4018-4025	Studies	_
29-14	4026-4027	,	_
29-15	4028-4030	to	_
29-16	4031-4038	exclude	_
29-17	4039-4040	a	_
29-18	4041-4047	family	_
29-19	4048-4055	history	_
29-20	4056-4058	of	_
29-21	4059-4068	psychotic	_
29-22	4069-4078	disorders	_
29-23	4079-4080	(	_
29-24	4081-4083	in	_
29-25	4084-4090	first-	_
29-26	4091-4093	or	_
29-27	4094-4107	second-degree	_
29-28	4108-4117	relatives	_
29-29	4118-4119	)	_
29-30	4120-4121	.	_

30-1	4122-4131	Exclusion	_
30-2	4132-4140	criteria	_
30-3	4141-4144	for	_
30-4	4145-4148	all	_
30-5	4149-4161	participants	_
30-6	4162-4170	included	_
30-7	4171-4172	a	_
30-8	4173-4180	history	_
30-9	4181-4183	of	_
30-10	4184-4188	head	_
30-11	4189-4195	trauma	_
30-12	4196-4198	or	_
30-13	4199-4204	major	_
30-14	4205-4212	medical	_
30-15	4213-4215	or	_
30-16	4216-4228	neurological	_
30-17	4229-4236	illness	_
30-18	4237-4238	.	_

31-1	4239-4242	All	_
31-2	4243-4255	participants	_
31-3	4256-4260	were	_
31-4	4261-4268	between	_
31-5	4269-4271	18	_
31-6	4272-4275	and	_
31-7	4276-4278	60	_
31-8	4279-4284	years	_
31-9	4285-4287	of	_
31-10	4288-4291	age	_
31-11	4292-4294	at	_
31-12	4295-4298	the	_
31-13	4299-4303	time	_
31-14	4304-4306	of	_
31-15	4307-4316	inclusion	_
31-16	4317-4318	.	_

32-1	4319-4331	Demographics	_
32-2	4332-4335	and	_
32-3	4336-4344	clinical	_
32-4	4345-4356	information	_
32-5	4357-4360	are	_
32-6	4361-4370	described	_
32-7	4371-4373	in	_
32-8	4374-4379	Table	_
32-9	4380-4381	1	_
32-10	4382-4383	.	_

33-1	4384-4388	Data	_
33-2	4389-4400	acquisition	_
33-3	4401-4404	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-4	4405-4410	scans	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-5	4411-4415	were	_
33-6	4416-4424	acquired	_
33-7	4425-4427	on	_
33-8	4428-4431	two	_
33-9	4432-4435	1.5	_
33-10	4436-4437	T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
33-11	4438-4445	Philips	http://maven.renci.org/NeuroBridge/neurobridge#2Level
33-12	4446-4453	Achieva	http://maven.renci.org/NeuroBridge/neurobridge#2Level
33-13	4454-4462	scanners	_
33-14	4463-4465	at	_
33-15	4466-4469	the	_
33-16	4470-4480	University	_
33-17	4481-4488	Medical	_
33-18	4489-4495	Center	_
33-19	4496-4503	Utrecht	_
33-20	4504-4505	,	_
33-21	4506-4510	with	_
33-22	4511-4514	the	_
33-23	4515-4519	same	_
33-24	4520-4531	acquisition	_
33-25	4532-4540	protocol	_
33-26	4541-4542	.	_

34-1	4543-4546	The	_
34-2	4547-4554	scanner	_
34-3	4555-4566	information	_
34-4	4567-4570	was	_
34-5	4571-4579	included	_
34-6	4580-4582	as	_
34-7	4583-4584	a	_
34-8	4585-4594	covariate	_
34-9	4595-4597	in	_
34-10	4598-4605	further	_
34-11	4606-4623	group-comparisons	_
34-12	4624-4625	.	_

35-1	4626-4629	For	_
35-2	4630-4634	each	_
35-3	4635-4642	subject	_
35-4	4643-4644	,	_
35-5	4645-4658	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-6	4659-4669	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-7	4670-4678	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-8	4679-4688	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-9	4689-4696	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-10	4697-4698	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-11	4699-4703	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-12	4704-4705	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-13	4706-4710	time	_
35-14	4711-4717	series	_
35-15	4718-4722	were	_
35-16	4723-4731	acquired	_
35-17	4732-4736	with	_
35-18	4737-4738	a	_
35-19	4739-4744	three	_
35-20	4745-4756	dimensional	_
35-21	4757-4758	(	_
35-22	4759-4761	3D	_
35-23	4762-4763	)	_
35-24	4764-4768	echo	_
35-25	4769-4777	shifting	_
35-26	4778-4782	with	_
35-27	4783-4784	a	_
35-28	4785-4790	train	_
35-29	4791-4793	of	_
35-30	4794-4806	observations	_
35-31	4807-4808	(	_
35-32	4809-4815	PRESTO	_
35-33	4816-4817	)	_
35-34	4818-4829	acquisition	_
35-35	4830-4836	scheme	_
35-36	4837-4838	.	_

36-1	4839-4842	The	_
36-2	4843-4849	PRESTO	_
36-3	4850-4858	protocol	_
36-4	4859-4867	combines	_
36-5	4868-4871	the	_
36-6	4872-4876	echo	_
36-7	4877-4885	shifting	_
36-8	4886-4895	technique	_
36-9	4896-4900	with	_
36-10	4901-4909	multiple	_
36-11	4910-4918	gradient	_
36-12	4919-4925	echoes	_
36-13	4926-4929	per	_
36-14	4930-4940	excitation	_
36-15	4941-4943	to	_
36-16	4944-4949	allow	_
36-17	4950-4953	for	_
36-18	4954-4955	a	_
36-19	4956-4966	repetition	_
36-20	4967-4971	time	_
36-21	4972-4979	shorter	_
36-22	4980-4984	than	_
36-23	4985-4989	echo	_
36-24	4990-4994	time	_
36-25	4995-4996	.	_

37-1	4997-5000	The	_
37-2	5001-5012	acquisition	_
37-3	5013-5023	parameters	_
37-4	5024-5028	were	_
37-5	5029-5030	:	_
37-6	5031-5033	TR	_
37-7	5034-5035	/	_
37-8	5036-5038	TE	_
37-9	5039-5040	=	_
37-10	5041-5045	21.1	_
37-11	5046-5047	/	_
37-12	5048-5052	31.1	_
37-13	5053-5055	ms	_
37-14	5056-5057	;	_
37-15	5058-5062	flip	_
37-16	5063-5068	angle	_
37-17	5069-5070	=	_
37-18	5071-5074	90°	_
37-19	5075-5076	;	_
37-20	5077-5082	field	_
37-21	5083-5085	of	_
37-22	5086-5090	view	_
37-23	5091-5092	=	_
37-24	5093-5096	256	_
37-25	5097-5098	×	_
37-26	5099-5102	256	_
37-27	5103-5106	mm2	_
37-28	5107-5108	,	_
37-29	5109-5114	voxel	_
37-30	5115-5119	size	_
37-31	5120-5121	=	_
37-32	5122-5123	4	_
37-33	5124-5125	×	_
37-34	5126-5127	4	_
37-35	5128-5129	×	_
37-36	5130-5131	4	_
37-37	5132-5135	mm3	_
37-38	5136-5137	,	_
37-39	5138-5141	900	_
37-40	5142-5146	time	_
37-41	5147-5153	frames	_
37-42	5154-5155	,	_
37-43	5156-5166	consisting	_
37-44	5167-5169	of	_
37-45	5170-5172	32	_
37-46	5173-5179	slices	_
37-47	5180-5188	covering	_
37-48	5189-5194	whole	_
37-49	5195-5200	brain	_
37-50	5201-5202	.	_

38-1	5203-5205	In	_
38-2	5206-5214	addition	_
38-3	5215-5216	,	_
38-4	5217-5218	a	_
38-5	5219-5230	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-6	5231-5235	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-7	5236-5239	was	_
38-8	5240-5249	collected	_
38-9	5250-5252	as	_
38-10	5253-5263	anatomical	_
38-11	5264-5273	reference	_
38-12	5274-5278	with	_
38-13	5279-5282	the	_
38-14	5283-5292	following	_
38-15	5293-5301	scanning	_
38-16	5302-5312	parameters	_
38-17	5313-5314	:	_
38-18	5315-5320	TR/TE	_
38-19	5321-5322	=	_
38-20	5323-5329	30/4.6	_
38-21	5330-5332	ms	_
38-22	5333-5334	;	_
38-23	5335-5339	flip	_
38-24	5340-5345	angle	_
38-25	5346-5347	=	_
38-26	5348-5351	30°	_
38-27	5352-5353	;	_
38-28	5354-5359	field	_
38-29	5360-5362	of	_
38-30	5363-5367	view	_
38-31	5368-5369	=	_
38-32	5370-5373	256	_
38-33	5374-5375	×	_
38-34	5376-5379	256	_
38-35	5380-5383	mm2	_
38-36	5384-5385	,	_
38-37	5386-5391	voxel	_
38-38	5392-5396	size	_
38-39	5397-5398	=	_
38-40	5399-5400	1	_
38-41	5401-5402	×	_
38-42	5403-5404	1	_
38-43	5405-5406	×	_
38-44	5407-5410	1.2	_
38-45	5411-5414	mm3	_
38-46	5415-5416	.	_

39-1	5417-5421	Data	_
39-2	5422-5435	preprocessing	_
39-3	5436-5449	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
39-4	5450-5454	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
39-5	5455-5459	data	_
39-6	5460-5464	were	_
39-7	5465-5477	preprocessed	_
39-8	5478-5483	using	_
39-9	5484-5487	the	_
39-10	5488-5492	Data	_
39-11	5493-5503	Processing	_
39-12	5504-5507	and	_
39-13	5508-5516	Analysis	_
39-14	5517-5520	for	_
39-15	5521-5526	Brain	_
39-16	5527-5534	Imaging	_
39-17	5535-5536	(	_
39-18	5537-5542	DPABI	_
39-19	5543-5544	)	_
39-20	5545-5552	toolbox	_
39-21	5553-5555	on	_
39-22	5556-5562	MATLAB	_
39-23	5563-5565	v.	_
39-24	5566-5572	R2016a	_
39-25	5573-5574	(	_
39-26	5575-5584	Mathworks	_
39-27	5585-5586	)	_
39-28	5587-5588	.	_

40-1	5589-5592	For	_
40-2	5593-5598	every	_
40-3	5599-5606	subject	_
40-4	5607-5608	,	_
40-5	5609-5612	the	_
40-6	5613-5618	first	_
40-7	5619-5621	10	_
40-8	5622-5632	functional	_
40-9	5633-5640	volumes	_
40-10	5641-5645	were	_
40-11	5646-5653	removed	_
40-12	5654-5656	to	_
40-13	5657-5662	allow	_
40-14	5663-5666	for	_
40-15	5667-5673	signal	_
40-16	5674-5687	stabilization	_
40-17	5688-5689	.	_

41-1	5690-5693	The	_
41-2	5694-5698	rest	_
41-3	5699-5701	of	_
41-4	5702-5705	the	_
41-5	5706-5716	functional	_
41-6	5717-5723	images	_
41-7	5724-5728	were	_
41-8	5729-5738	realigned	_
41-9	5739-5740	,	_
41-10	5741-5754	co-registered	_
41-11	5755-5759	with	_
41-12	5760-5765	their	_
41-13	5766-5776	individual	_
41-14	5777-5785	anatomic	_
41-15	5786-5791	image	_
41-16	5792-5793	,	_
41-17	5794-5797	and	_
41-18	5798-5807	corrected	_
41-19	5808-5811	for	_
41-20	5812-5820	nuisance	_
41-21	5821-5830	variables	_
41-22	5831-5832	(	_
41-23	5833-5836	six	_
41-24	5837-5842	rigid	_
41-25	5843-5854	realignment	_
41-26	5855-5865	parameters	_
41-27	5866-5867	,	_
41-28	5868-5874	signal	_
41-29	5875-5880	drift	_
41-30	5881-5882	,	_
41-31	5883-5891	averaged	_
41-32	5892-5898	signal	_
41-33	5899-5903	from	_
41-34	5904-5909	white	_
41-35	5910-5916	matter	_
41-36	5917-5920	and	_
41-37	5921-5934	cerebrospinal	_
41-38	5935-5940	fluid	_
41-39	5941-5942	)	_
41-40	5943-5948	using	_
41-41	5949-5950	a	_
41-42	5951-5957	linear	_
41-43	5958-5968	regression	_
41-44	5969-5974	model	_
41-45	5975-5976	.	_

42-1	5977-5986	Band-pass	_
42-2	5987-5996	filtering	_
42-3	5997-5998	(	_
42-4	5999-6007	0.01–0.1	_
42-5	6008-6010	Hz	_
42-6	6011-6012	)	_
42-7	6013-6016	was	_
42-8	6017-6024	applied	_
42-9	6025-6027	to	_
42-10	6028-6032	fMRI	_
42-11	6033-6044	time-series	_
42-12	6045-6047	to	_
42-13	6048-6054	reduce	_
42-14	6055-6062	effects	_
42-15	6063-6065	of	_
42-16	6066-6079	low-frequency	_
42-17	6080-6086	drifts	_
42-18	6087-6090	and	_
42-19	6091-6105	high-frequency	_
42-20	6106-6111	noise	_
42-21	6112-6113	.	_

43-1	6114-6126	Subsequently	_
43-2	6127-6128	,	_
43-3	6129-6132	the	_
43-4	6133-6143	functional	_
43-5	6144-6149	scans	_
43-6	6150-6154	were	_
43-7	6155-6164	spatially	_
43-8	6165-6175	normalized	_
43-9	6176-6178	to	_
43-10	6179-6182	MNI	_
43-11	6183-6188	space	_
43-12	6189-6194	using	_
43-13	6195-6196	a	_
43-14	6197-6206	symmetric	_
43-15	6207-6221	group-specific	_
43-16	6222-6224	T1	_
43-17	6225-6233	template	_
43-18	6234-6235	,	_
43-19	6236-6239	and	_
43-20	6240-6249	resampled	_
43-21	6250-6252	to	_
43-22	6253-6254	3	_
43-23	6255-6256	×	_
43-24	6257-6258	3	_
43-25	6259-6260	×	_
43-26	6261-6262	3	_
43-27	6263-6266	mm3	_
43-28	6267-6273	voxels	_
43-29	6274-6275	.	_

44-1	6276-6283	Spatial	_
44-2	6284-6293	smoothing	_
44-3	6294-6297	was	_
44-4	6298-6305	applied	_
44-5	6306-6308	to	_
44-6	6309-6319	normalized	_
44-7	6320-6326	images	_
44-8	6327-6331	with	_
44-9	6332-6333	a	_
44-10	6334-6335	4	_
44-11	6336-6338	mm	_
44-12	6339-6349	full-width	_
44-13	6350-6362	half-maximum	_
44-14	6363-6364	(	_
44-15	6365-6369	FWHM	_
44-16	6370-6371	)	_
44-17	6372-6380	Gaussian	_
44-18	6381-6387	kernel	_
44-19	6388-6389	.	_

45-1	6390-6392	In	_
45-2	6393-6397	view	_
45-3	6398-6400	of	_
45-4	6401-6407	recent	_
45-5	6408-6416	findings	_
45-6	6417-6419	on	_
45-7	6420-6423	the	_
45-8	6424-6433	influence	_
45-9	6434-6436	of	_
45-10	6437-6447	in-scanner	_
45-11	6448-6452	head	_
45-12	6453-6459	motion	_
45-13	6460-6462	on	_
45-14	6463-6467	fMRI	_
45-15	6468-6475	signals	_
45-16	6476-6477	,	_
45-17	6478-6484	images	_
45-18	6485-6489	with	_
45-19	6490-6499	excessive	_
45-20	6500-6508	movement	_
45-21	6509-6510	(	_
45-22	6511-6521	frame-wise	_
45-23	6522-6534	displacement	_
45-24	6535-6536	>	_
45-25	6537-6540	0.5	_
45-26	6541-6543	mm	_
45-27	6544-6545	)	_
45-28	6546-6549	and	_
45-29	6550-6551	1	_
45-30	6552-6560	backward	_
45-31	6561-6564	and	_
45-32	6565-6566	2	_
45-33	6567-6574	forward	_
45-34	6575-6580	scans	_
45-35	6581-6589	relative	_
45-36	6590-6592	to	_
45-37	6593-6596	the	_
45-38	6597-6603	marked	_
45-39	6604-6609	frame	_
45-40	6610-6611	,	_
45-41	6612-6616	were	_
45-42	6617-6625	scrubbed	_
45-43	6626-6627	.	_

46-1	6628-6631	The	_
46-2	6632-6641	scrubbing	_
46-3	6642-6651	procedure	_
46-4	6652-6659	negated	_
46-5	6660-6677	group-differences	_
46-6	6678-6680	in	_
46-7	6681-6685	head	_
46-8	6686-6692	motion	_
46-9	6693-6694	(	_
46-10	6695-6701	before	_
46-11	6702-6711	scrubbing	_
46-12	6712-6713	χ	_
46-13	6714-6715	(	_
46-14	6716-6717	2	_
46-15	6718-6719	)	_
46-16	6720-6721	2	_
46-17	6722-6723	=	_
46-18	6724-6728	6.20	_
46-19	6729-6730	,	_
46-20	6731-6732	p	_
46-21	6733-6734	=	_
46-22	6735-6738	.04	_
46-23	6739-6742	and	_
46-24	6743-6748	after	_
46-25	6749-6758	scrubbing	_
46-26	6759-6760	χ	_
46-27	6761-6762	(	_
46-28	6763-6764	2	_
46-29	6765-6766	)	_
46-30	6767-6768	2	_
46-31	6769-6770	=	_
46-32	6771-6775	4.09	_
46-33	6776-6777	,	_
46-34	6778-6779	p	_
46-35	6780-6781	=	_
46-36	6782-6785	.13	_
46-37	6786-6787	,	_
46-38	6788-6801	Supplementary	_
46-39	6802-6807	Table	_
46-40	6808-6809	1	_
46-41	6810-6811	)	_
46-42	6812-6813	,	_
46-43	6814-6817	and	_
46-44	6818-6821	did	_
46-45	6822-6825	not	_
46-46	6826-6830	lead	_
46-47	6831-6833	to	_
46-48	6834-6845	differences	_
46-49	6846-6848	on	_
46-50	6849-6852	the	_
46-51	6853-6859	number	_
46-52	6860-6862	of	_
46-53	6863-6869	images	_
46-54	6870-6878	rejected	_
46-55	6879-6884	among	_
46-56	6885-6888	the	_
46-57	6889-6894	three	_
46-58	6895-6902	subject	_
46-59	6903-6909	groups	_
46-60	6910-6911	(	_
46-61	6912-6913	χ	_
46-62	6914-6915	(	_
46-63	6916-6917	2	_
46-64	6918-6919	)	_
46-65	6920-6921	2	_
46-66	6922-6923	=	_
46-67	6924-6928	3.54	_
46-68	6929-6930	,	_
46-69	6931-6932	p	_
46-70	6933-6934	=	_
46-71	6935-6938	.17	_
46-72	6939-6940	)	_
46-73	6941-6942	.	_

47-1	6943-6946	The	_
47-2	6947-6961	Harvard-Oxford	_
47-3	6962-6967	atlas	_
47-4	6968-6971	was	_
47-5	6972-6979	applied	_
47-6	6980-6982	to	_
47-7	6983-6994	whole-brain	_
47-8	6995-7005	functional	_
47-9	7006-7010	data	_
47-10	7011-7013	in	_
47-11	7014-7019	order	_
47-12	7020-7022	to	_
47-13	7023-7033	parcellate	_
47-14	7034-7037	the	_
47-15	7038-7043	brain	_
47-16	7044-7048	into	_
47-17	7049-7052	112	_
47-18	7053-7062	bilateral	_
47-19	7063-7070	regions	_
47-20	7071-7072	(	_
47-21	7073-7075	48	_
47-22	7076-7084	cortical	_
47-23	7085-7088	and	_
47-24	7089-7090	8	_
47-25	7091-7102	subcortical	_
47-26	7103-7110	regions	_
47-27	7111-7114	per	_
47-28	7115-7125	hemisphere	_
47-29	7126-7127	)	_
47-30	7128-7129	.	_

48-1	7130-7136	Region	_
48-2	7137-7142	names	_
48-3	7143-7144	,	_
48-4	7145-7158	abbreviations	_
48-5	7159-7160	,	_
48-6	7161-7169	anatomic	_
48-7	7170-7184	classification	_
48-8	7185-7186	(	_
48-9	7187-7194	frontal	_
48-10	7195-7196	,	_
48-11	7197-7205	temporal	_
48-12	7206-7207	,	_
48-13	7208-7216	parietal	_
48-14	7217-7218	,	_
48-15	7219-7228	occipital	_
48-16	7229-7233	lobe	_
48-17	7234-7235	,	_
48-18	7236-7245	cingulate	_
48-19	7246-7252	cortex	_
48-20	7253-7256	and	_
48-21	7257-7268	subcortical	_
48-22	7269-7276	regions	_
48-23	7277-7278	)	_
48-24	7279-7282	and	_
48-25	7283-7293	functional	_
48-26	7294-7303	hierarchy	_
48-27	7304-7305	(	_
48-28	7306-7313	primary	_
48-29	7314-7326	sensorimotor	_
48-30	7327-7334	regions	_
48-31	7335-7336	,	_
48-32	7337-7345	unimodal	_
48-33	7346-7347	,	_
48-34	7348-7359	heteromodal	_
48-35	7360-7371	association	_
48-36	7372-7377	areas	_
48-37	7378-7379	,	_
48-38	7380-7381	(	_
48-39	7382-7386	para	_
48-40	7387-7388	)	_
48-41	7389-7395	limbic	_
48-42	7396-7399	and	_
48-43	7400-7411	subcortical	_
48-44	7412-7419	regions	_
48-45	7420-7421	)	_
48-46	7422-7425	are	_
48-47	7426-7436	referenced	_
48-48	7437-7439	in	_
48-49	7440-7453	Supplementary	_
48-50	7454-7459	Table	_
48-51	7460-7461	2	_
48-52	7462-7463	.	_

49-1	7464-7467	The	_
49-2	7468-7478	functional	_
49-3	7479-7488	hierarchy	_
49-4	7489-7500	subdivision	_
49-5	7501-7507	scheme	_
49-6	7508-7510	is	_
49-7	7511-7516	based	_
49-8	7517-7519	on	_
49-9	7520-7528	previous	_
49-10	7529-7536	studies	_
49-11	7537-7538	.	_

50-1	7539-7547	Regional	_
50-2	7548-7559	time-series	_
50-3	7560-7564	were	_
50-4	7565-7573	averaged	_
50-5	7574-7580	across	_
50-6	7581-7587	voxels	_
50-7	7588-7589	,	_
50-8	7590-7593	and	_
50-9	7594-7610	cross-correlated	_
50-10	7611-7614	for	_
50-11	7615-7619	each	_
50-12	7620-7624	pair	_
50-13	7625-7627	of	_
50-14	7628-7633	brain	_
50-15	7634-7641	regions	_
50-16	7642-7647	using	_
50-17	7648-7655	Pearson	_
50-18	7656-7658	's	_
50-19	7659-7670	correlation	_
50-20	7671-7672	.	_

51-1	7673-7684	Correlation	_
51-2	7685-7697	coefficients	_
51-3	7698-7702	were	_
51-4	7703-7712	converted	_
51-5	7713-7715	to	_
51-6	7716-7717	z	_
51-7	7718-7724	scores	_
51-8	7725-7730	using	_
51-9	7731-7737	Fisher	_
51-10	7738-7740	's	_
51-11	7741-7742	z	_
51-12	7743-7757	transformation	_
51-13	7758-7759	,	_
51-14	7760-7767	serving	_
51-15	7768-7770	as	_
51-16	7771-7772	a	_
51-17	7773-7780	measure	_
51-18	7781-7783	of	_
51-19	7784-7794	functional	_
51-20	7795-7807	connectivity	_
51-21	7808-7816	strength	_
51-22	7817-7824	between	_
51-23	7825-7828	two	_
51-24	7829-7836	regions	_
51-25	7837-7838	.	_

52-1	7839-7855	Interhemispheric	_
52-2	7856-7868	connectivity	_
52-3	7869-7872	The	_
52-4	7873-7878	level	_
52-5	7879-7881	of	_
52-6	7882-7892	functional	_
52-7	7893-7905	connectivity	_
52-8	7906-7913	between	_
52-9	7914-7916	56	_
52-10	7917-7924	regions	_
52-11	7925-7927	in	_
52-12	7928-7931	one	_
52-13	7932-7942	hemisphere	_
52-14	7943-7946	and	_
52-15	7947-7952	their	_
52-16	7953-7966	corresponding	_
52-17	7967-7972	areas	_
52-18	7973-7975	in	_
52-19	7976-7979	the	_
52-20	7980-7985	other	_
52-21	7986-7996	hemisphere	_
52-22	7997-7999	is	_
52-23	8000-8004	used	_
52-24	8005-8009	here	_
52-25	8010-8012	as	_
52-26	8013-8016	the	_
52-27	8017-8024	measure	_
52-28	8025-8027	of	_
52-29	8028-8044	interhemispheric	_
52-30	8045-8057	connectivity	_
52-31	8058-8059	.	_

53-1	8060-8076	Interhemispheric	_
53-2	8077-8088	connections	_
53-3	8089-8096	between	_
53-4	8097-8106	homotopic	_
53-5	8107-8114	regions	_
53-6	8115-8118	are	_
53-7	8119-8124	among	_
53-8	8125-8128	the	_
53-9	8129-8138	strongest	_
53-10	8139-8149	functional	_
53-11	8150-8162	associations	_
53-12	8163-8165	in	_
53-13	8166-8183	cortical-cortical	_
53-14	8184-8196	interactions	_
53-15	8197-8200	and	_
53-16	8201-8205	have	_
53-17	8206-8214	reliably	_
53-18	8215-8219	been	_
53-19	8220-8230	identified	_
53-20	8231-8233	in	_
53-21	8234-8238	both	_
53-22	8239-8246	healthy	_
53-23	8247-8250	and	_
53-24	8251-8259	clinical	_
53-25	8260-8271	populations	_
53-26	8272-8273	.	_

54-1	8274-8276	As	_
54-2	8277-8278	a	_
54-3	8279-8292	supplementary	_
54-4	8293-8301	analysis	_
54-5	8302-8303	,	_
54-6	8304-8321	group-differences	_
54-7	8322-8324	in	_
54-8	8325-8336	heterotopic	_
54-9	8337-8353	interhemispheric	_
54-10	8354-8366	connectivity	_
54-11	8367-8370	and	_
54-12	8371-8375	left	_
54-13	8376-8379	and	_
54-14	8380-8385	right	_
54-15	8386-8402	intrahemispheric	_
54-16	8403-8415	connectivity	_
54-17	8416-8420	were	_
54-18	8421-8429	examined	_
54-19	8430-8432	in	_
54-20	8433-8436	the	_
54-21	8437-8441	same	_
54-22	8442-8448	manner	_
54-23	8449-8451	as	_
54-24	8452-8461	homotopic	_
54-25	8462-8478	interhemispheric	_
54-26	8479-8491	connectivity	_
54-27	8492-8493	.	_

55-1	8494-8502	Moreover	_
55-2	8503-8504	,	_
55-3	8505-8507	to	_
55-4	8508-8514	assess	_
55-5	8515-8518	the	_
55-6	8519-8530	consistency	_
55-7	8531-8533	of	_
55-8	8534-8550	interhemispheric	_
55-9	8551-8563	connectivity	_
55-10	8564-8576	measurements	_
55-11	8577-8584	between	_
55-12	8585-8592	studies	_
55-13	8593-8594	,	_
55-14	8595-8597	we	_
55-15	8598-8607	performed	_
55-16	8608-8610	an	_
55-17	8611-8621	additional	_
55-18	8622-8630	analysis	_
55-19	8631-8640	examining	_
55-20	8641-8644	the	_
55-21	8645-8656	correlation	_
55-22	8657-8659	in	_
55-23	8660-8668	regional	_
55-24	8669-8685	interhemispheric	_
55-25	8686-8698	connectivity	_
55-26	8699-8701	in	_
55-27	8702-8710	controls	_
55-28	8711-8718	between	_
55-29	8719-8723	this	_
55-30	8724-8729	study	_
55-31	8730-8733	and	_
55-32	8734-8737	the	_
55-33	8738-8743	study	_
55-34	8744-8746	of	_
55-35	8747-8748	.	_

56-1	8749-8760	Hemispheric	_
56-2	8761-8775	specialization	_
56-3	8776-8787	Hemispheric	_
56-4	8788-8802	specialization	_
56-5	8803-8805	is	_
56-6	8806-8816	calculated	_
56-7	8817-8821	here	_
56-8	8822-8824	as	_
56-9	8825-8828	the	_
56-10	8829-8839	difference	_
56-11	8840-8842	in	_
56-12	8843-8855	connectivity	_
56-13	8856-8864	strength	_
56-14	8865-8872	between	_
56-15	8873-8889	intrahemispheric	_
56-16	8890-8893	and	_
56-17	8894-8905	heterotopic	_
56-18	8906-8922	interhemispheric	_
56-19	8923-8934	connections	_
56-20	8935-8937	of	_
56-21	8938-8942	each	_
56-22	8943-8948	brain	_
56-23	8949-8955	region	_
56-24	8956-8957	.	_

57-1	8958-8967	Homotopic	_
57-2	8968-8984	interhemispheric	_
57-3	8985-8996	connections	_
57-4	8997-9001	were	_
57-5	9002-9005	not	_
57-6	9006-9010	used	_
57-7	9011-9013	in	_
57-8	9014-9017	the	_
57-9	9018-9029	calculation	_
57-10	9030-9032	of	_
57-11	9033-9044	hemispheric	_
57-12	9045-9059	specialization	_
57-13	9060-9062	so	_
57-14	9063-9067	that	_
57-15	9068-9070	we	_
57-16	9071-9076	could	_
57-17	9077-9084	examine	_
57-18	9085-9097	relationship	_
57-19	9098-9105	between	_
57-20	9106-9117	hemispheric	_
57-21	9118-9132	specialization	_
57-22	9133-9136	and	_
57-23	9137-9153	interhemispheric	_
57-24	9154-9166	connectivity	_
57-25	9167-9169	in	_
57-26	9170-9173	the	_
57-27	9174-9183	following	_
57-28	9184-9192	analysis	_
57-29	9193-9194	.	_

58-1	9195-9196	A	_
58-2	9197-9205	positive	_
58-3	9206-9211	value	_
58-4	9212-9214	of	_
58-5	9215-9226	hemispheric	_
58-6	9227-9241	specialization	_
58-7	9242-9251	indicates	_
58-8	9252-9256	that	_
58-9	9257-9258	a	_
58-10	9259-9265	region	_
58-11	9266-9268	or	_
58-12	9269-9279	hemisphere	_
58-13	9280-9282	is	_
58-14	9283-9297	preferentially	_
58-15	9298-9307	connected	_
58-16	9308-9310	to	_
58-17	9311-9316	other	_
58-18	9317-9324	regions	_
58-19	9325-9331	within	_
58-20	9332-9335	its	_
58-21	9336-9339	own	_
58-22	9340-9350	hemisphere	_
58-23	9351-9352	,	_
58-24	9353-9360	whereas	_
58-25	9361-9362	a	_
58-26	9363-9371	negative	_
58-27	9372-9377	value	_
58-28	9378-9386	suggests	_
58-29	9387-9391	that	_
58-30	9392-9393	a	_
58-31	9394-9400	region	_
58-32	9401-9403	or	_
58-33	9404-9414	hemisphere	_
58-34	9415-9417	is	_
58-35	9418-9422	more	_
58-36	9423-9431	strongly	_
58-37	9432-9441	connected	_
58-38	9442-9444	to	_
58-39	9445-9452	regions	_
58-40	9453-9455	in	_
58-41	9456-9459	the	_
58-42	9460-9473	contralateral	_
58-43	9474-9484	hemisphere	_
58-44	9485-9486	.	_

59-1	9487-9490	The	_
59-2	9491-9497	method	_
59-3	9498-9502	used	_
59-4	9503-9505	to	_
59-5	9506-9513	compute	_
59-6	9514-9525	hemispheric	_
59-7	9526-9540	specialization	_
59-8	9541-9546	using	_
59-9	9547-9556	intrinsic	_
59-10	9557-9567	functional	_
59-11	9568-9580	connectivity	_
59-12	9581-9584	has	_
59-13	9585-9589	been	_
59-14	9590-9599	described	_
59-15	9600-9602	in	_
59-16	9603-9611	previous	_
59-17	9612-9619	studies	_
59-18	9620-9625	using	_
59-19	9626-9627	a	_
59-20	9628-9639	voxel-based	_
59-21	9640-9648	analysis	_
59-22	9649-9650	.	_

60-1	9651-9662	Statistical	_
60-2	9663-9671	analysis	_
60-3	9672-9679	Effects	_
60-4	9680-9682	of	_
60-5	9683-9688	group	_
60-6	9689-9692	and	_
60-7	9693-9703	covariates	_
60-8	9704-9706	on	_
60-9	9707-9723	interhemispheric	_
60-10	9724-9736	connectivity	_
60-11	9737-9740	and	_
60-12	9741-9752	hemispheric	_
60-13	9753-9767	specialization	_
60-14	9768-9772	were	_
60-15	9773-9781	assessed	_
60-16	9782-9787	using	_
60-17	9788-9800	linear-mixed	_
60-18	9801-9807	effect	_
60-19	9808-9814	models	_
60-20	9815-9816	.	_

61-1	9817-9820	For	_
61-2	9821-9837	interhemispheric	_
61-3	9838-9850	connectivity	_
61-4	9851-9852	,	_
61-5	9853-9866	fixed-effects	_
61-6	9867-9874	include	_
61-7	9875-9876	:	_
61-8	9877-9882	group	_
61-9	9883-9889	status	_
61-10	9890-9891	(	_
61-11	9892-9900	controls	_
61-12	9901-9902	,	_
61-13	9903-9911	siblings	_
61-14	9912-9913	,	_
61-15	9914-9922	patients	_
61-16	9923-9924	)	_
61-17	9925-9926	,	_
61-18	9927-9930	age	_
61-19	9931-9932	,	_
61-20	9933-9936	sex	_
61-21	9937-9938	,	_
61-22	9939-9949	handedness	_
61-23	9950-9951	(	_
61-24	9952-9957	right	_
61-25	9958-9959	/	_
61-26	9960-9964	left	_
61-27	9965-9966	/	_
61-28	9967-9972	mixed	_
61-29	9973-9974	)	_
61-30	9975-9976	,	_
61-31	9977-9984	scanner	_
61-32	9985-9986	(	_
61-33	9987-9988	#	_
61-34	9989-9990	1	_
61-35	9991-9992	/	_
61-36	9993-9994	#	_
61-37	9995-9996	2	_
61-38	9997-9998	)	_
61-39	9999-10002	and	_
61-40	10003-10007	head	_
61-41	10008-10014	motion	_
61-42	10015-10016	.	_

62-1	10017-10019	To	_
62-2	10020-10027	control	_
62-3	10028-10031	for	_
62-4	10032-10041	potential	_
62-5	10042-10059	group-differences	_
62-6	10060-10062	in	_
62-7	10063-10069	global	_
62-8	10070-10082	connectivity	_
62-9	10083-10084	,	_
62-10	10085-10089	mean	_
62-11	10090-10102	connectivity	_
62-12	10103-10111	strength	_
62-13	10112-10114	of	_
62-14	10115-10118	all	_
62-15	10119-10132	non-homotopic	_
62-16	10133-10144	connections	_
62-17	10145-10146	(	_
62-18	10147-10151	i.e.	_
62-19	10152-10153	,	_
62-20	10154-10157	all	_
62-21	10158-10174	intrahemispheric	_
62-22	10175-10178	and	_
62-23	10179-10190	heterotopic	_
62-24	10191-10207	interhemispheric	_
62-25	10208-10219	connections	_
62-26	10220-10221	)	_
62-27	10222-10225	was	_
62-28	10226-10234	included	_
62-29	10235-10237	as	_
62-30	10238-10239	a	_
62-31	10240-10252	fixed-effect	_
62-32	10253-10257	term	_
62-33	10258-10259	(	_
62-34	10260-10266	global	_
62-35	10267-10269	FC	_
62-36	10270-10271	)	_
62-37	10272-10273	.	_

63-1	10274-10280	Family	_
63-2	10281-10283	ID	_
63-3	10284-10285	,	_
63-4	10286-10294	encoding	_
63-5	10295-10298	the	_
63-6	10299-10307	subjects	_
63-7	10308-10309	'	_
63-8	10310-10318	pedigree	_
63-9	10319-10330	information	_
63-10	10331-10332	,	_
63-11	10333-10336	was	_
63-12	10337-10345	included	_
63-13	10346-10348	as	_
63-14	10349-10362	random-effect	_
63-15	10363-10367	term	_
63-16	10368-10370	to	_
63-17	10371-10378	control	_
63-18	10379-10382	for	_
63-19	10383-10389	family	_
63-20	10390-10394	ties	_
63-21	10395-10402	between	_
63-22	10403-10411	subjects	_
63-23	10412-10413	(	_
63-24	10414-10416	Eq	_
63-25	10417-10418	.	_

64-1	10419-10420	(	_
64-2	10421-10422	1	_
64-3	10423-10424	)	_
64-4	10425-10426	)	_
64-5	10427-10428	.	_

65-1	10429-10432	The	_
65-2	10433-10438	model	_
65-3	10439-10442	has	_
65-4	10443-10446	237	_
65-5	10447-10459	observations	_
65-6	10460-10461	(	_
65-7	10462-10468	number	_
65-8	10469-10471	of	_
65-9	10472-10480	subjects	_
65-10	10481-10485	with	_
65-11	10486-10494	complete	_
65-12	10495-10506	information	_
65-13	10507-10508	)	_
65-14	10509-10510	,	_
65-15	10511-10514	and	_
65-16	10515-10517	10	_
65-17	10518-10523	fixed	_
65-18	10524-10528	term	_
65-19	10529-10539	predictors	_
65-20	10540-10541	(	_
65-21	10542-10550	constant	_
65-22	10551-10552	,	_
65-23	10553-10566	group_sibling	_
65-24	10567-10568	,	_
65-25	10569-10582	group_patient	_
65-26	10583-10584	,	_
65-27	10585-10588	age	_
65-28	10589-10590	,	_
65-29	10591-10604	gender_female	_
65-30	10605-10606	,	_
65-31	10607-10622	handedness_left	_
65-32	10623-10624	,	_
65-33	10625-10641	handedness_mixed	_
65-34	10642-10643	,	_
65-35	10644-10652	scanner_	_
65-36	10653-10654	#	_
65-37	10655-10656	2	_
65-38	10657-10658	,	_
65-39	10659-10665	motion	_
65-40	10666-10667	,	_
65-41	10668-10674	global	_
65-42	10675-10677	FC	_
65-43	10678-10679	)	_
65-44	10680-10681	,	_
65-45	10682-10689	leaving	_
65-46	10690-10691	=	_
65-47	10692-10698	237–10	_
65-48	10699-10700	=	_
65-49	10701-10704	227	_
65-50	10705-10713	residual	_
65-51	10714-10721	degrees	_
65-52	10722-10724	of	_
65-53	10725-10732	freedom	_
65-54	10733-10734	.	_

66-1	10735-10743	Equation	_
66-2	10744-10745	1	_
66-3	10746-10747	:	_
66-4	10748-10751	For	_
66-5	10752-10763	hemispheric	_
66-6	10764-10778	specialization	_
66-7	10779-10780	,	_
66-8	10781-10786	group	_
66-9	10787-10793	status	_
66-10	10794-10795	,	_
66-11	10796-10799	age	_
66-12	10800-10801	,	_
66-13	10802-10805	sex	_
66-14	10806-10807	,	_
66-15	10808-10818	handedness	_
66-16	10819-10820	,	_
66-17	10821-10828	scanner	_
66-18	10829-10832	and	_
66-19	10833-10837	head	_
66-20	10838-10844	motion	_
66-21	10845-10849	were	_
66-22	10850-10855	again	_
66-23	10856-10864	included	_
66-24	10865-10867	as	_
66-25	10868-10880	fixed-effect	_
66-26	10881-10886	terms	_
66-27	10887-10888	.	_

67-1	10889-10901	Additionally	_
67-2	10902-10903	,	_
67-3	10904-10906	we	_
67-4	10907-10915	included	_
67-5	10916-10926	hemisphere	_
67-6	10927-10929	as	_
67-7	10930-10931	a	_
67-8	10932-10937	fixed	_
67-9	10938-10944	factor	_
67-10	10945-10947	to	_
67-11	10948-10955	examine	_
67-12	10956-10965	potential	_
67-13	10966-10977	differences	_
67-14	10978-10980	in	_
67-15	10981-10993	connectivity	_
67-16	10994-11002	patterns	_
67-17	11003-11010	between	_
67-18	11011-11014	the	_
67-19	11015-11018	two	_
67-20	11019-11030	hemispheres	_
67-21	11031-11032	.	_

68-1	11033-11039	Random	_
68-2	11040-11046	effect	_
68-3	11047-11052	terms	_
68-4	11053-11060	include	_
68-5	11061-11067	family	_
68-6	11068-11070	ID	_
68-7	11071-11074	and	_
68-8	11075-11082	subject	_
68-9	11083-11085	ID	_
68-10	11086-11092	nested	_
68-11	11093-11099	within	_
68-12	11100-11106	family	_
68-13	11107-11109	ID	_
68-14	11110-11111	.	_

69-1	11112-11115	The	_
69-2	11116-11122	number	_
69-3	11123-11125	of	_
69-4	11126-11131	fixed	_
69-5	11132-11136	term	_
69-6	11137-11147	predictors	_
69-7	11148-11150	is	_
69-8	11151-11153	10	_
69-9	11154-11155	(	_
69-10	11156-11164	constant	_
69-11	11165-11166	,	_
69-12	11167-11180	group_sibling	_
69-13	11181-11182	,	_
69-14	11183-11196	group_patient	_
69-15	11197-11198	,	_
69-16	11199-11202	age	_
69-17	11203-11204	,	_
69-18	11205-11218	gender_female	_
69-19	11219-11220	,	_
69-20	11221-11236	handedness_left	_
69-21	11237-11238	,	_
69-22	11239-11255	handedness_mixed	_
69-23	11256-11257	,	_
69-24	11258-11266	scanner_	_
69-25	11267-11268	#	_
69-26	11269-11270	2	_
69-27	11271-11272	,	_
69-28	11273-11279	motion	_
69-29	11280-11281	,	_
69-30	11282-11295	hemisphere_RH	_
69-31	11296-11297	)	_
69-32	11298-11299	,	_
69-33	11300-11303	and	_
69-34	11304-11312	residual	_
69-35	11313-11320	degrees	_
69-36	11321-11323	of	_
69-37	11324-11331	freedom	_
69-38	11332-11334	is	_
69-39	11335-11338	237	_
69-40	11339-11340	×	_
69-41	11341-11342	2	_
69-42	11343-11344	(	_
69-43	11345-11355	hemisphere	_
69-44	11356-11357	)	_
69-45	11358-11359	–	_
69-46	11360-11362	10	_
69-47	11363-11364	=	_
69-48	11365-11368	464	_
69-49	11369-11370	.	_

70-1	11371-11379	Equation	_
70-2	11380-11381	2	_
70-3	11382-11383	:	_
70-4	11384-11396	Linear-mixed	_
70-5	11397-11404	effects	_
70-6	11405-11413	analysis	_
70-7	11414-11417	was	_
70-8	11418-11423	first	_
70-9	11424-11431	applied	_
70-10	11432-11434	to	_
70-11	11435-11442	overall	_
70-12	11443-11459	interhemispheric	_
70-13	11460-11472	connectivity	_
70-14	11473-11476	and	_
70-15	11477-11488	hemispheric	_
70-16	11489-11503	specialization	_
70-17	11504-11505	(	_
70-18	11506-11507	p	_
70-19	11508-11509	<	_
70-20	11510-11513	.05	_
70-21	11514-11515	)	_
70-22	11516-11517	,	_
70-23	11518-11521	and	_
70-24	11522-11526	then	_
70-25	11527-11529	to	_
70-26	11530-11534	each	_
70-27	11535-11537	of	_
70-28	11538-11540	56	_
70-29	11541-11549	regional	_
70-30	11550-11562	measurements	_
70-31	11563-11564	,	_
70-32	11565-11576	controlling	_
70-33	11577-11580	for	_
70-34	11581-11589	multiple	_
70-35	11590-11601	comparisons	_
70-36	11602-11603	(	_
70-37	11604-11605	p	_
70-38	11606-11607	<	_
70-39	11608-11611	.05	_
70-40	11612-11613	,	_
70-41	11614-11624	Bonferroni	_
70-42	11625-11634	corrected	_
70-43	11635-11636	)	_
70-44	11637-11638	.	_

71-1	11639-11646	Overall	_
71-2	11647-11650	and	_
71-3	11651-11659	regional	_
71-4	11660-11672	measurements	_
71-5	11673-11677	with	_
71-6	11678-11689	significant	_
71-7	11690-11695	group	_
71-8	11696-11703	effects	_
71-9	11704-11708	were	_
71-10	11709-11718	subjected	_
71-11	11719-11721	to	_
71-12	11722-11730	post-hoc	_
71-13	11731-11740	bivariate	_
71-14	11741-11752	comparisons	_
71-15	11753-11760	between	_
71-16	11761-11765	each	_
71-17	11766-11770	pair	_
71-18	11771-11773	of	_
71-19	11774-11781	subject	_
71-20	11782-11788	groups	_
71-21	11789-11790	(	_
71-22	11791-11792	p	_
71-23	11793-11794	<	_
71-24	11795-11798	.05	_
71-25	11799-11800	)	_
71-26	11801-11802	.	_

72-1	11803-11815	Relationship	_
72-2	11816-11823	between	_
72-3	11824-11840	interhemispheric	_
72-4	11841-11853	connectivity	_
72-5	11854-11857	and	_
72-6	11858-11869	hemispheric	_
72-7	11870-11884	specialization	_
72-8	11885-11887	To	_
72-9	11888-11892	test	_
72-10	11893-11900	whether	_
72-11	11901-11922	schizophrenia-related	_
72-12	11923-11930	changes	_
72-13	11931-11933	in	_
72-14	11934-11950	interhemispheric	_
72-15	11951-11963	connectivity	_
72-16	11964-11971	co-vary	_
72-17	11972-11976	with	_
72-18	11977-11988	alterations	_
72-19	11989-11991	in	_
72-20	11992-12003	hemispheric	_
72-21	12004-12018	specialization	_
72-22	12019-12020	,	_
72-23	12021-12023	we	_
72-24	12024-12034	calculated	_
72-25	12035-12038	the	_
72-26	12039-12043	mean	_
72-27	12044-12054	difference	_
72-28	12055-12062	between	_
72-29	12063-12071	controls	_
72-30	12072-12075	and	_
72-31	12076-12084	patients	_
72-32	12085-12087	on	_
72-33	12088-12092	both	_
72-34	12093-12105	measurements	_
72-35	12106-12109	for	_
72-36	12110-12114	each	_
72-37	12115-12120	brain	_
72-38	12121-12127	region	_
72-39	12128-12129	.	_

73-1	12130-12137	Pearson	_
73-2	12138-12140	's	_
73-3	12141-12152	correlation	_
73-4	12153-12161	analysis	_
73-5	12162-12165	was	_
73-6	12166-12175	performed	_
73-7	12176-12178	on	_
73-8	12179-12196	group-differences	_
73-9	12197-12199	of	_
73-10	12200-12216	interhemispheric	_
73-11	12217-12229	connectivity	_
73-12	12230-12233	and	_
73-13	12234-12245	hemispheric	_
73-14	12246-12260	specialization	_
73-15	12261-12267	across	_
73-16	12268-12275	regions	_
73-17	12276-12277	(	_
73-18	12278-12279	p	_
73-19	12280-12281	<	_
73-20	12282-12285	.05	_
73-21	12286-12287	)	_
73-22	12288-12289	.	_

74-1	12290-12293	The	_
74-2	12294-12298	same	_
74-3	12299-12307	analysis	_
74-4	12308-12311	was	_
74-5	12312-12321	performed	_
74-6	12322-12325	for	_
74-7	12326-12334	siblings	_
74-8	12335-12337	as	_
74-9	12338-12346	compared	_
74-10	12347-12349	to	_
74-11	12350-12358	patients	_
74-12	12359-12360	,	_
74-13	12361-12364	and	_
74-14	12365-12368	for	_
74-15	12369-12377	controls	_
74-16	12378-12386	compared	_
74-17	12387-12389	to	_
74-18	12390-12398	siblings	_
74-19	12399-12400	.	_

75-1	12401-12412	Correlation	_
75-2	12413-12420	between	_
75-3	12421-12433	connectivity	_
75-4	12434-12444	alteration	_
75-5	12445-12448	and	_
75-6	12449-12457	clinical	_
75-7	12458-12465	factors	_
75-8	12466-12468	To	_
75-9	12469-12476	examine	_
75-10	12477-12480	the	_
75-11	12481-12490	potential	_
75-12	12491-12499	clinical	_
75-13	12500-12509	relevance	_
75-14	12510-12512	of	_
75-15	12513-12525	connectivity	_
75-16	12526-12533	changes	_
75-17	12534-12536	in	_
75-18	12537-12545	patients	_
75-19	12546-12547	,	_
75-20	12548-12551	the	_
75-21	12552-12557	level	_
75-22	12558-12560	of	_
75-23	12561-12577	interhemispheric	_
75-24	12578-12590	connectivity	_
75-25	12591-12594	and	_
75-26	12595-12606	hemispheric	_
75-27	12607-12621	specialization	_
75-28	12622-12626	were	_
75-29	12627-12637	correlated	_
75-30	12638-12642	with	_
75-31	12643-12650	illness	_
75-32	12651-12659	duration	_
75-33	12660-12663	and	_
75-34	12664-12669	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
75-35	12670-12675	total	_
75-36	12676-12682	scores	_
75-37	12683-12685	in	_
75-38	12686-12694	patients	_
75-39	12695-12696	(	_
75-40	12697-12698	p	_
75-41	12699-12700	<	_
75-42	12701-12704	.05	_
75-43	12705-12706	)	_
75-44	12707-12708	.	_

76-1	12709-12717	Moreover	_
76-2	12718-12719	,	_
76-3	12720-12733	antipsychotic	_
76-4	12734-12744	medication	_
76-5	12745-12748	was	_
76-6	12749-12757	examined	_
76-7	12758-12760	as	_
76-8	12761-12762	a	_
76-9	12763-12772	potential	_
76-10	12773-12783	confounder	_
76-11	12784-12786	of	_
76-12	12787-12797	functional	_
76-13	12798-12810	connectivity	_
76-14	12811-12823	measurements	_
76-15	12824-12826	by	_
76-16	12827-12838	correlating	_
76-17	12839-12844	daily	_
76-18	12845-12855	medication	_
76-19	12856-12858	in	_
76-20	12859-12873	chlorpromazine	_
76-21	12874-12884	equivalent	_
76-22	12885-12889	dose	_
76-23	12890-12894	with	_
76-24	12895-12911	interhemispheric	_
76-25	12912-12924	connectivity	_
76-26	12925-12928	and	_
76-27	12929-12940	hemispheric	_
76-28	12941-12955	specialization	_
76-29	12956-12957	.	_

